Navigation Links
Sangamo BioSciences Reports Second Quarter 2008 Financial Results
Date:7/23/2008

the treatment of critical limb ischemia. The data from this trial demonstrated that administration of the ZFP transcription factor resulted in a statistically significant increase in circulating stem cells in the peripheral blood. In addition, within a subgroup in which bone marrow cells were examined before and after treatment, the data suggests that subjects who showed the most marked clinical improvements, as judged by limb salvage, ulcer healing, reduction in pain and increased oxygen concentrations in the tissues of the lower limbs, also showed the greatest increase in bone marrow stem cells. This observation of stem cell mobilization after treatment with Sangamo's ZFP TF activator of VEGF-A, is being further investigated in an ongoing Phase 2 trial of SB-509, SB-509-703.

-- Announcement of research and license agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche) for the use of ZFP technology to develop transgenic animals. In July, Sangamo and Sigma-Aldrich Corporation jointly announced a research and license agreement to provide Roche with non-exclusive, worldwide rights for the use of Sangamo's ZFP nuclease (ZFN(TM)) technology to develop cell-lines and transgenic animals with targeted modifications in a specified gene in a specified species. Roche also has an option for an exclusive, worldwide license from Sangamo for the commercial use of such ZFN-generated transgenic animals in the production of therapeutic and diagnostic products.

-- Publication of preclinical data in Nature Biotechnology. Papers highlighting therapeutic and research applications of Sangamo's ZFN technology were published in the scientific journal, Nature Biotechnology. The first paper demonstrated the use of ZFNs to efficiently generate transgenic animals, in this case zebrafish, a widely recognized system for human disease modeling and in vivo drug discovery. A second publication described the successful ZFN-mediated disruption of the CCR5 gene in hu
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Sangamo BioSciences Announces Second Quarter Conference Call and Webcast
2. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
3. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
4. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
5. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
6. Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
7. Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors
8. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
9. Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
10. Sangamo BioSciences to Present at the Cowen and Company 28th Annual Health Care Conference
11. Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... VANCOUVER , March 31, 2015  /PRNewswire/ - ESSA ... today that it has filed with the Food and ... Drug ("IND") application related to the Company,s proposed clinical ... the IND application is required in order for ESSA ... The IND application is a complete ...
(Date:3/31/2015)... FRANCISCO , March 31, 2015  Sonoa Health, ... Australia , has developed a world-first consumer health ... records, medication prescriptions, wearable devices and more. ... Stewart as its CEO, who brings to the ... corporate advisory, which has included working closely with the ...
(Date:3/31/2015)... NEW YORK , March 31, 2015 /PRNewswire/ ... biopharmaceutical company advancing protein biologic therapies and oncology ... marketing partner, Hanmi Pharmaceutical Co., Ltd ("Hanmi") (KSE: ... the country,s Ministry of Food and Drug Safety ... (KTR) for MuGard, its oncology supportive-care treatment for ...
(Date:3/31/2015)... March 31, 2015 Diasome Pharmaceuticals, Inc. ... SDG, Inc., that a United States patent has recently ... therapy. , Entitled “Lipid Construct for Delivery ... of matter claims related to the use of Diasome’s ... enabling injected insulin to more effectively reach the liver’s ...
Breaking Biology Technology:ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 2ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 3ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 4Investment Banker Appointed CEO of Australian Health Tech Start-Up 2Investment Banker Appointed CEO of Australian Health Tech Start-Up 3PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 2PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 3Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2
... researchers have successfully synthesized a DNA-based memory loop in ... in the emerging field of synthetic biology. , ... in the lab of Professor Pamela Silver, a faculty ... not only reconstructed the dynamics of memory, but also ...
... Sept. 14 Viragen, Inc. (OTC,Bulletin Board: ... (OTC Bulletin Board: VRGE), today jointly announced,that ... Umea, Sweden, filed an application seeking protection ... Multiferon(R), a,multi-subtype, human alpha interferon. The ...
... September 14, Rosetta Genomics Ltd (Nasdaq: ROSG ... and therapeutics, announced,today that Amir Avniel, Rosetta Genomics, ... Thursday, September 20, at 5:00 pm EDT at ... live audio webcast of the presentation will be ...
Cached Biology Technology:Scientists synthesize memory in yeast cells 2Scientists synthesize memory in yeast cells 3Viragen International's Subsidiary, ViraNative AB, Files to Seek Bankruptcy Protection in Sweden 2Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference 2
(Date:3/18/2015)... 18, 2015 As mobile payments become ... smart wallets and apps continue to be introduced into the ... the mobile payment industry in focus today are:  NXT-ID, Inc. ... BABA ), Apple Inc. (NASDAQ: AAPL ... Inc. (NASDAQ: FB ) NXT-ID, Inc. ...
(Date:3/16/2015)... 16, 2015 Between 16 ... present groundbreaking innovations in biometric identification at the ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... is well at the forefront: the company,s all ... in Germany . BiometricGate is ...
(Date:3/12/2015)... VIEW, Calif. , March 12, 2015 /PRNewswire/ ... with Complimentary Registration here: http://bit.ly/1G7Os0L . SPEAKERS: ... Manager Aravind SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 ... in order to compete in several different markets ... market is currently witnessing an uptrend. ...
Breaking Biology News(10 mins):Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... May 22, 2013 Early screening for prostate cancer could ... for women, thanks to UC Irvine research published today in ... After more than a decade of work, UC Irvine chemists ... for prostate cancer in urine, meaning that the disease could ...
... concept of "place" is increasingly being considered in the ... new resource that can help them recognize and respond ... their lives. Place-Based Conservation: Perspectives from the ... Northwest Research Station,s Linda Kruger, can help managers take ...
... Mo. Cancers of all types become most deadly when ... has reached this stage, it becomes very difficult for doctors ... Now, researchers at the University of Missouri have found a ... wherever they may be in the body. Michael Lewis, an ...
Cached Biology News:UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3MU researchers develop radioactive nanoparticles that target cancer cells 2
... is used for the synthesis of 5' ... reactions. Substitution of cap analog for a ... in vitro transcription reaction results in the ... large fraction of the transcripts. Capped mRNAs ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
... Description: Beta-Agarase is useful in recovering ... agarose. Beta-Agarase digests the agarose into ... Properties: Heat Inactivation: 65C, 15 min ... 6.5 Purity: Tested for contaminating endonucleases, ...
... A modified nucleotide structure called ... 5?-end of most naturally-occurring eukaryotic mRNAs ... Cap Analog for a portion of ... vitro transcription reaction results in the ...
Biology Products: